A scientific review published in Lipids in Health and Disease examines the pharmacological mechanisms governing injectable adipose tissue reduction, charting a paradigm shift from nonselective cytolytic destruction toward targeted adipocyte apoptosis and metabolic modulation. Conducted by researchers including Seo Kyoung Park, Jin Kyoung Choi, Jong Wook Shin, Min Kyung Pyo, Jun Hwi Ko, Do Su Lim, A. M. Abd El-Aty, Tae Woo Jung, and Ji Hoon Jeong, the analysis evaluated literature published between 1990 and 2026 indexed across PubMed, Scopus, and Web of Science. The review notes that the clinical demand for minimally invasive approaches designed to reduce localized adipose tissue has grown substantially alongside the ongoing expansion of aesthetic medicine. However, while injectable reduction therapies have been administered clinically for decades, the authors state that their fundamental pharmacological mechanisms remain incompletely understood from the perspective of adipocyte biology.
To clarify these processes, the authors critically analyzed classical cytolytic agents, identifying deoxycholic acid as the primary clinically validated benchmark in this category. According to the evidence, classical cytolytic agents reduce localized adipose tissue predominantly via detergent-mediated membrane disruption, which triggers necrotic adipocyte cell death, cellular rupture, and subsequent lipid release. Although the clinical efficacy of deoxycholic acid is robustly confirmed through human clinical validation, the review emphasizes that its underlying mode of action depends fundamentally on nonspecific membrane injury and secondary local inflammation. Consequently, these established detergent-based interventions exhibit limited cellular selectivity, affecting surrounding cellular membranes alongside target fat cells.
In contrast to cytolytic approaches, metabolic and signaling-based agents alter cellular energetics rather than directly destroying fat cells. The researchers evaluated interventions involving beta-adrenergic agonists, phosphodiesterase inhibitors, and adenosine monophosphate-activated protein kinase (AMPK) modulators. Mechanistically, these compounds primarily regulate intracellular lipid mobilization, cellular fatty acid utilization, and fatty acid oxidation pathways without causing adipocyte elimination. While these metabolic regulators directly influence lipid handling, the review observes that published scientific evidence supporting durable, long-term localized fat reduction through these signaling strategies remains limited, largely because the underlying adipocyte population remains viable.
The literature indicates that newer pharmacological strategies increasingly represent a shift toward mechanism-defined modes of adipocyte elimination. Preclinical research assessing purified phosphatidylcholine-based formulations, such as the experimental candidate AYP-101, demonstrates an alternative biological mechanism distinct from crude detergent lysis. In preclinical in vitro and in vivo models, purified phosphatidylcholine has been shown to induce toll-like receptor 4 (TLR4)-associated nuclear factor-kappa B (NF-κB) and tumor necrosis factor-alpha (TNF-α) signaling cascades. This molecular activation drives downstream lipolytic and apoptotic responses, pointing toward regulated cellular elimination pathways rather than random necrotic injury.
The review also evaluated emerging clinical-stage candidates that embody distinct mechanisms of adipocyte removal, distinguishing between targeted apoptosis and liponecrotic destruction. Clinical reports examining the investigational agent CBL-514 detail a proposed apoptosis-oriented mechanism linked to dual-specificity tyrosine-phosphorylation-regulated kinase 1B (DYRK1B), which operates via downstream regulation of Bax and Bcl-2 proteins to trigger programmed cell death. In contrast, the candidate RZL-012 represents a separate liponecrotic approach, functioning through direct cellular membrane injury followed by localized inflammatory clearance mechanisms.
While apoptosis-oriented therapies theoretically offer regulated and controlled adipocyte elimination, the authors caution that their comparative tissue selectivity still requires thorough clinical validation in human trials. The authors stress that it is critical to explicitly distinguish between preclinical in vitro or in vivo findings and verified human clinical trial data when evaluating any of these therapeutic agents. Concurrently, molecular targeting platforms, including emerging RNA-based interventions and adipose-targeted delivery systems, are developing as novel strategies designed to precisely modulate adipogenic pathways and inflammatory remodeling with enhanced anatomical and cellular specificity.
Ultimately, the authors argue for reframing the scientific field away from simple localized fat volume reduction and toward the comprehensive regulation of adipocyte fate, lipid handling, and inflammatory remodeling. By systematically comparing the major injectable strategies according to their pharmacological actions, limitations, and translational potential, the review seeks to support the development of safer, mechanism-grounded interventions. The researchers conclude that these targeted pharmacological frameworks may eventually transcend aesthetic applications, offering therapeutic potential for the clinical modulation of dysfunctional adipose tissue in obesity.
Subject of Research: Pharmacological mechanisms of injectable adipose reduction therapies
Article Title: Pharmacological mechanisms of injectable adipose reduction: a paradigm shift from nonselective cytolysis to targeted adipocyte apoptosis and metabolic modulation
Article References: Park, S. K., Choi, J. K., Shin, J. W., Pyo, M. K., Ko, J. H., Lim, D. S., Abd El-Aty, A. M., Jung, T. W., & Jeong, J. H. (2026). Pharmacological mechanisms of injectable adipose reduction: a paradigm shift from nonselective cytolysis to targeted adipocyte apoptosis and metabolic modulation. Lipids in Health and Disease. https://doi.org/10.1186/s12944-026-03101-2
Image Credits: AI Generated
DOI: 10.1186/s12944-026-03101-2
Keywords: adipose reduction, adipocyte apoptosis, deoxycholic acid, cytolysis, phosphatidylcholine, AYP-101, CBL-514, RZL-012, lipolysis, fatty acid oxidation, AMPK modulators, DYRK1B, TLR4 signaling, adipose tissue remodeling, injectable lipolysis, aesthetic medicine, NF-κB signaling, targeted delivery systems
News Source: Ophelia Keating. (November 18, 2026). Review Highlights Shift Toward Targeted Apoptosis in Injectable Fat Reduction. Scienmag.



